This market resolves to Yes if, by December 31, 2026, the cost of semaglutide (brands including Wegovy and Ozempic) is available for purchase at below $10 per month in at least five low-income countries, as reported by a reputable source such as the World Health Organization or a major pharmaceutical company report.